Identifying trajectories of fatigue in patients with primary mitochondrial disease due to the m.3243A > G variant
Publication year
2022Source
Journal of Inherited Metabolic Disease, 45, 6, (2022), pp. 1130-1142ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Psychology
Paediatrics
Gynaecology
Internal Medicine
Journal title
Journal of Inherited Metabolic Disease
Volume
vol. 45
Issue
iss. 6
Page start
p. 1130
Page end
p. 1142
Subject
Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 6: Metabolic Disorders RIHS: Radboud Institute for Health Sciences; Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences; Internal Medicine - Radboud University Medical Center; Medical Psychology - Radboud University Medical Center; Paediatrics - Radboud University Medical CenterAbstract
Severe fatigue is a common complaint in patients with primary mitochondrial disease. However, less is known about the course of fatigue over time. This longitudinal observational cohort study of patients with the mitochondrial DNA 3243 A>G variant explored trajectories of fatigue over 2 years, and characteristics of patients within these fatigue trajectories. Fifty-three adult patients treated at the Radboud University Medical Center Nijmegen were included. The majority of the patients reported consistent, severe fatigue (41%), followed by patients with a mixed pattern of severe and mild fatigue (36%). Then, 23% of patients reported stable mild fatigue levels. Patients with a stable high fatigue trajectory were characterized by higher disease manifestations scores, more clinically relevant mental health symptoms, and lower psychosocial functioning and quality of life compared to patients reporting stable low fatigue levels. Fatigue at baseline and disease manifestation scores predicted fatigue severity at the 2-year assessment (57% explained variance). This study demonstrates that severe fatigue is a common and stable complaint in the majority of patients. Clinicians should be aware of severe fatigue in patients with moderate to severe disease manifestation scores on the Newcastle Mitochondrial Disease Scale, the high prevalence of clinically relevant mental health symptoms and overall impact on quality of life in these patients. Screening of fatigue and psychosocial variables will guide suitable individualized treatment to improve the quality of life.
This item appears in the following Collection(s)
- Academic publications [246764]
- Electronic publications [134241]
- Faculty of Medical Sciences [93461]
- Open Access publications [107769]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.